Literature DB >> 3419593

Multiple sclerosis: a serial study using MRI in relapsing patients.

C Isaac1, D K Li, M Genton, C Jardine, E Grochowski, M Palmer, L F Kastrukoff, J Oger, D W Paty.   

Abstract

Prospective monthly magnetic resonance imaging (MRI) studies were done over 6 months in seven relapsing MS patients. MRI and neurologic evaluations were compared for sensitivity in detecting disease activity. Four patients were clinically stable throughout the study. Three patients had five clinical relapses, two localized to the spinal cord and three to the brainstem. Eighteen new and ten enlarging MRI lesions were seen in five patients. Most lesions were less than 10 mm in diameter. All were clinically silent. Two patients developed major enlarging MRI lesions (seen in three slices) which increased in size over 2 months and then gradually became smaller over 2 months, leaving behind small residual areas of abnormality. There were 36 follow-up scans, 17 of which (47%) showed evidence for increasing activity. Thirteen (36%) of the scans had new lesions, most of them being small. This study shows that MRI evidence for disease activity in MS is much more frequent than is clinical evidence.

Entities:  

Mesh:

Year:  1988        PMID: 3419593     DOI: 10.1212/wnl.38.10.1511

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  28 in total

1.  Dirty-appearing white matter in multiple sclerosis: volumetric MR imaging and magnetization transfer ratio histogram analysis.

Authors:  Yulin Ge; Robert I Grossman; James S Babb; Juan He; Lois J Mannon
Journal:  AJNR Am J Neuroradiol       Date:  2003 Nov-Dec       Impact factor: 3.825

2.  Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines.

Authors:  D H Miller; F Barkhof; I Berry; L Kappos; G Scotti; A J Thompson
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-08       Impact factor: 10.154

3.  Neuropsychological assessment in multiple sclerosis: a follow-up study with magnetic resonance imaging.

Authors:  C Mariani; E Farina; S F Cappa; G P Anzola; L Faglia; L Bevilacqua; R Capra; F Mattioli; L A Vignolo
Journal:  J Neurol       Date:  1991-10       Impact factor: 4.849

Review 4.  Magnetic resonance imaging of multiple sclerosis lesions. Measuring outcome in treatment trials.

Authors:  J H Simon
Journal:  West J Med       Date:  1996-06

5.  Exploratory treatment trials in multiple sclerosis using MRI: sample size calculations for relapsing-remitting and secondary progressive subgroups using placebo controlled parallel groups.

Authors:  N Tubridy; H J Ader; F Barkhof; A J Thompson; D H Miller
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-01       Impact factor: 10.154

6.  Biochemical changes within a multiple sclerosis plaque in vivo.

Authors:  T A Cadoux-Hudson; A Kermode; B Rajagopalan; D Taylor; A J Thompson; I E Ormerod; W I McDonald; G K Radda
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-11       Impact factor: 10.154

Review 7.  Imaging as an Outcome Measure in Multiple Sclerosis.

Authors:  Daniel Ontaneda; Robert J Fox
Journal:  Neurotherapeutics       Date:  2017-01       Impact factor: 7.620

8.  Database for serial magnetic resonance imaging in multiple sclerosis.

Authors:  F Barkhof; A J Thompson; L Kappos; J J Nauta; T Yousri; I Berry; G Scotti; B Appel; P S Tofts; D H Miller
Journal:  Neuroradiology       Date:  1993       Impact factor: 2.804

9.  The role of qualitative and quantitative MRI assessment of multiple sclerosis lesions according to their in evaluating the efficacy of intravenous immunoglobulin G.

Authors:  B Koçer; S Yildirim-Gürel; E T Tali; C Irkeç; S Işik
Journal:  Neuroradiology       Date:  2004-03-04       Impact factor: 2.804

10.  Patient-orientated longitudinal study of multiple sclerosis in south west England (The South West Impact of Multiple Sclerosis Project, SWIMS) 1: protocol and baseline characteristics of cohort.

Authors:  John P Zajicek; Wendy M Ingram; Jane Vickery; Siobhan Creanor; Dave E Wright; Jeremy C Hobart
Journal:  BMC Neurol       Date:  2010-10-07       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.